Health Care & Life Sciences » Biotechnology | Thrombogenics

Thrombogenics

Thrombogenics N.V.
Stock Exchange Other OTC
EPS
 $1.18
Market Cap
 $192.8 M
Shares Outstanding
 38.27 M
Public Float
 -

Profile

Address
Gaston Geenslaan 1
Leuven VL 3001
Belgium
Employees -
Website http://www.oxurion.com
Updated 07/08/2019
ThromboGenics NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. It operates under JETREA (ocriplasmin) brand name. The company was founded by Desire Collen in 1991 and is headquartered in Leuven, Belgium.

Financials

View All
Created with Highcharts 5.0.14Thrombogenics N.V.Net Income. Fiscal year is January-December. All values EUR Thousands.26 40126 40151 11551 11537 88437 88460 31460 31422 78822 78838 47438 474201320142015201620172018010k20k30k40k50k60k70k
Created with Highcharts 5.0.14Thrombogenics N.V.Sales/Revenue. Fiscal year is January-December. All values EUR Thousands.112 781112 78113 77613 77611 19811 1987 1047 1049 0559 0555 3205 320201320142015201620172018025k50k75k100k125k

Patrik de Haes
Chief Executive Officer & Executive Director
Paul G. Howes
Non-Executive Director
View All

StatInvestor

Privacy Policy
Feedback

© 2025 StatInvestor All Rights Reserved.